Interleukin-6 promotes androgen-independent growth in LNCaP human prostate cancer cells

Clinical Cancer Research

Volumn 9, Issue 1 I, 2003, Pages 370-376

  Lee, Soo Ok ^b   Lou, Wei ^b   Hou, Min ^b   De Miguel, Fernando ^a   Gerber, Lizabeth ^a   Gao, Allen C ^b,c  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; INTERLEUKIN 6;

ANCHORAGE INDEPENDENT GROWTH; ANTIGEN EXPRESSION; ARTICLE; CANCER CELL; DRUG EFFECT; EPITHELIUM CELL; GENETIC REGULATION; GROWTH INHIBITION; HORMONAL REGULATION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR GROWTH;

ANIMALS; BLOTTING, NORTHERN; BLOTTING, WESTERN; CELL DIVISION; CELL NUCLEUS; COLORING AGENTS; DISEASE PROGRESSION; DNA-BINDING PROTEINS; HUMANS; INTERLEUKIN-6; MALE; MICE; PHENOTYPE; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STAT3 TRANSCRIPTION FACTOR; TETRAZOLIUM SALTS; THIAZOLES; TIME FACTORS; TRANS-ACTIVATORS; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED;

EID: 1842668004     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Isaacs, J. T. Role of androgens in prostatic cancer. Vitam. Horm., 49: 433-502, 1994.
2. Culig, Z., Hobisch, A., Hittmair, A., Cronauer, M. V., Radmayr, C., Zhang, J., Bartsch. G., and Klocker, H. Synergistic activation of androgen receptor by androgen and luteinizing hormone-releasing hormone in prostatic carcinoma cells. Prostate, 32: 106-114, 1997.
3. Linja, M. J., Savinainen, K. J., Saramaki, O. R., Tammela, T. L., Vessella, R. L., and Visakorpi, T. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res., 61: 3550-3555, 2001.
4. Yeh, S., Lin, H. K., Kang, H. Y., Thin, T. H., Lin, M. F., and Chang, C. From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc. Natl. Acad. Sci. USA, 96: 5458-5463, 1999.
5. Craft, N., Shostak, Y., Carey, M., and Sawyers, C. L. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat. Med., 5: 280-285, 1999.
6. Akira, S., Taga, T., and Kishimoto, T. Interleukin-6 in biology and medicine. Adv. Immunol., 54: 1-78, 1993.
7. Murakami, M., Hibi, M., Nakagawa, N., Nakagawa, T., Yasukawa, K., Yamanishi, K., Taga, T., and Kishimoto, T. IL-6-induced homodimerization of gp130 and associated activation of a tyrosine kinase. Science (Wash. DC), 260: 1808-1810, 1993.
8. Akira, S., Nishio, Y., Inoue, M., Wang, X. J., Wei, S., Matsusaka, T., Yoshida, K., Sudo, T., Naruto, M., and Kishimoto, T. Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91- related transcription factor involved in the gp130-mediated signaling pathway. Cell, 77: 63-71, 1994.
9. Siegall, C. B., Schwab, G., Nordan, R. P., FitzGerald, D. J., and Pastan, I. Expression of the interleukin 6 receptor and interleukin 6 in prostate carcinoma cells. Cancer Res., 50: 7786-7788, 1990.
10. Siegsmund, M. J., Yamazaki, H., and Pastan, I. Interleukin 6 receptor mRNA in prostate carcinomas and benign prostate hyperplasia. J. Urol., 151: 1396-1399, 1994.
11. Hobisch, A., Rogatsch, H., Hittmair, A., Fuchs, D., Bartsch, G., Jr., Klocker, H., Bartsch, G., and Culig, Z. Immunohistochemical localization of interleukin-6 and its receptor in benign, premalignant and malignant prostate tissue. J. Pathol., 191: 239-244, 2000.
12. Drachenberg, D. E., Elgamal, A. A., Rowbotham, R., Peterson, M., and Murphy, G. P. Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer. Prostate, 41: 127-133, 1999.
13. Adler, H. L., McCurdy, M. A., Kattan, M. W., Timme, T. L., Scardino, P. T., and Thompson, T. C. Elevated levels of circulating interleukin-6 and transforming growth factor-β1 in patients with metastatic prostatic carcinoma. J. Urol., 161: 182-187, 1999.
14. Twillie, D. A., Eisenberger, M. A., Carducci, M. A., Hseih, W. S., Kim, W. Y., and Simons, J. W. Interleukin-6: a candidate mediator of human prostate cancer morbidity. Urology, 45: 542-549, 1995.
15. Okamoto, M., Lee, C., and Oyasu, R. Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro. Cancer Res., 57: 141-146, 1997.
16. Lou, W., Ni, Z., Dyer, K., Tweardy, D. J., and Gao, A. C. Interleukin-6 induces prostate cancer cell growth accompanied by activation of stat3 signaling pathway. Prostate, 42: 239-242, 2000.
17. Lin, D. L., Whitney, M. C., Yao, Z., and Keller, E. T. Interleukin-6 induces androgen responsiveness in prostate cancer cells through upregulation of androgen receptor expression. Clin. Cancer Res., 7: 17731781, 2001.
18. Giri, D., Ozen, M., and Ittmann, M. Interleukin-6 is an autocrine growth factor in human prostate cancer. Am. J. Pathol., 159: 21592165, 2001.
19. Chung, T. D., Yu, J. J., Spiotto, M. T., Bartkowski, M., and Simons, J. W. Characterization of the role of IL-6 in the progression of prostate cancer. Prostate, 38: 199-207, 1999.
20. Chen, T., Wang, L. H., and Farrar, W. L. Interleukin 6 activates androgen receptor-mediated gene expression through a signal transducer and activator of transcription 3-dependent pathway in LNCaP prostate cancer cells. Cancer Res., 60: 2132-2135, 2000.
21. Hobisch, A., Eder, I. E., Putz, T., Horninger, W., Bartsch, G., Klocker, H., and Culig, Z. Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res., 58: 4640-4645, 1998.
22. Ueda, T., Bruchovsky, N., and Sadar, M. D. Activation of the androgen receptor N-terminal domain by IL-6 via MAPK and STAT3 signal transduction pathways. J. Biol. Chem., 277: 7076-7085, 2002.
23. DeMiguel, F., Lee, O. K., Lou, W., Xiao, X., Pflug, B. R., Nelson, J. B., and Gao, A. C. Stat3 enhances the growth of LNCaP human prostate cancer cells in intact and castrated male nude mice. Prostate, 52: 123-129, 2002.
24. Ni, Z., Lou, W., Leman, E. S., and Gao, A. C. Inhibition of constitutively activated Stat3 signaling pathway suppresses growth of prostate cancer cells. Cancer Res., 60: 1225-1228, 2000.
25. Foster, B. A., and Cunha, G. R. Efficacy of various natural and synthetic androgens to induce ductal branching morphogenesis in the developing anterior rat prostate. Endocrinology, 140: 318-328, 1999.
26. Chung, T. D., Yu, J. J., Kong, T. A., Spiotto, M. T., and Lin, J. M. Interleukin-6 activates phosphatidylinositol-3 kinase, which inhibits apoptosis in human prostate cancer cell lines. Prostate, 42: 1-7, 2000.
27. Deeble, P. D., Murphy, D. J., Parsons, S. J., and Cox, M. E. Interleukin-6- and cyclic AMP-mediated signaling potentiates neuroendocrine differentiation of LNCaP prostate tumor cells. Mol. Cell. Biol., 21: 8471-8482, 2001.
28. Qiu, Y., Ravi, L., and Kung, H. J. Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells. Nature (Lond.), 393: 83-85, 1998.
29. Qiu, Y., Robinson, D., Pretlow, T. G., and Kung, H. J. Etk/Bmx, a tyrosine kinase with a pleckstrin-homology domain, is an effector of phosphatidylinositol 3′-kinase and is involved in interleukin 6-induced neuroendocrine differentiation of prostate cancer cells. Proc. Natl. Acad. Sci. USA. 95: 3644-3649, 1998.